Did You Know...
...that Charles Goodyear performed some of his experiments on rubber while in debtor's prison? He was there so often he referred to it as his "hotel". Chronically in debt because of poor business sense and ill health, Goodyear depended on the generosity of friends and family. Even after he unlocked the secret to vulcanizing rubber, he was unable to improve his financial situation. When he died, his estate was $200,000 in debt.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8124584 | Macrocyclic hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I, II or III, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring s... | 02/28/2012 |
| 8101643 | Benzimidazole derivatives The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the co... | 01/24/2012 |
| 8048041 | Micro-valve A one-way valve comprises a seat and a membrane having an inner portion that is stretched over the seat, wherein, in use, the inner membrane portion is selectively deflected from the seat such that a fluid path is created from one side of the membrane to the other s... | 11/01/2011 |
| 8034388 | Anthocyanin-rich compositions and methods for inhibiting cancer cell growth The present invention provides compositions and methods for inhibiting the growth and cell cycle progression in carcinoma cells comprising the step of contacting the cells with an anthocyanin rich extract (ARE) in an amount effective to inhibit the growth and cell c... | 10/11/2011 |
| 7687459 | Arylalkoxyl hepatitis C virus protease inhibitors The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) N... | 03/30/2010 |
| 7662779 | Triazolyl macrocyclic hepatitis C serine protease inhibitors The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) N... | 02/16/2010 |
| 7655160 | Compositions of matter: system II The present invention relates to new compositions of matter, particularly metals and alloys, and methods of making such compositions. The new compositions of matter exhibit long-range ordering and unique electronic character. ... | 02/02/2010 |
| 7635683 | Quinoxalinyl tripeptide hepatitis C virus inhibitors The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS... | 12/22/2009 |
| 7622452 | C-9 alkenylidine bridged macrolides The present invention discloses compounds of formulae (I), (II) or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceuti... | 11/24/2009 |
| 7589067 | 6, 11-bridged tricyclic macrolides The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical comp... | 09/15/2009 |
| 7582605 | Phosphorus-containing hepatitis C serine protease inhibitors The present invention relates to phosphorus-derived compounds of Formula I or Formula II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A proteas... | 09/01/2009 |
| 7563877 | Processes for the preparation of -(2-aminobenzo[]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 The present invention relates to processes and intermediates for the preparation of 6-11 bicyclic erythromycin derivative known as EDP-182 (IX-a). In particular, the present invention relates to processes and intermediates for the preparation of O-(2-aminobenzo[d]ox... | 07/21/2009 |
